Ethos Technologies Inc.
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Warrior Ethos in Action: DUDE 44 Bravo’s Incredible Story - The White House (.gov)
Eli Lilly’s Engage Biologics Deal Extends Genetic Bets Beyond Obesity Boom
Eli Lilly (NYSE:LLY) has agreed to acquire Engage Biologics in a deal worth up to $202 million. Engage Biologics is developing Tethosome, a non-viral DNA delivery platform for genetic medicines. This transaction is Lilly’s seventh acquisition of 2026 and is intended to expand its genetic medicines capabilities. Eli Lilly comes into this deal with strong recent stock performance, with the share price at $1,041.65 and up 15.4% over the past 30 days and 3.5% over the past week. Over the past...
Eli Lilly acquires Engage Biologics for up to $202 million
The deal is Lilly's seventh acquisition of 2026 and centers on Engage's non-viral DNA delivery platform, Tethosome
Congressional Trades in $LIFE
No disclosed congressional trades found in $LIFE.
Insider Trades (Form 4)
Colis Peter George
Wang Lingke
Kucharski Brandt Walter
BOTHA ROELOF
SC US (TTGP), LTD.
Capozzi Christopher M.
Colis Peter George
Wang Lingke
Key People
Wang Lingke
President
SC US (TTGP) LTD
10% Owner
BOTHA ROELOF
Director
Capozzi Christopher M
Chief Financial Officer
Colis Peter George
CEO and Secretary
Kucharski Brandt Walter
Chief Accounting Officer
GV 2021 GP L P
10% Owner
Political Giving
$15,000 given to 1 candidate across 1 disclosed contribution (FEC Schedule A).
David Trone
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro